MetLife Investment Management’s Kindred Biosciences, Inc. KIN Stock Holding History

MetLife Investment Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,530	Closed	-$46.1K	–	2384
2020 Q1	$46.1K	Sell	11,530 -13,629	-54%	-$116K	﹤0.01%	2230
2019 Q4	$213K	Hold	25,159	–	–	﹤0.01%	1945
2019 Q3	$172K	Hold	25,159	–	–	﹤0.01%	2027
2019 Q2	$210K	Buy	25,159 +11,448	+83%	+$98.8K	﹤0.01%	2003
2019 Q1	$126K	Hold	13,711	–	–	﹤0.01%	2226
2018 Q4	$150K	Hold	13,711	–	–	﹤0.01%	2077
2018 Q3	$191K	Hold	13,711	–	–	﹤0.01%	2108
2018 Q2	$146K	Buy	+13,711	New	+$134K	﹤0.01%	2072

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's KIN Position: Q2 2020 in Review

MetLife Investment Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2020, closing a stake of 11,530 shares — an estimated $46.1K sold.

MetLife Investment Management first reported a position in KIN in Q2 2018 and held it in 8 quarters. The position peaked at $213K in Q4 2019. 83 funds tracked by Wall St. Rank hold KIN as of Q2 2020.

MetLife Investment Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
MetLife Investment Management sold 11,530 Kindred Biosciences, Inc. shares in Q2 2020, an estimated $46.1K.
MetLife Investment Management first reported a position in Kindred Biosciences, Inc. in Q2 2018 and held it in 8 quarters.
MetLife Investment Management's Kindred Biosciences, Inc. position peaked at $213K in Q4 2019.
83 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2020.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.